XBIT XBiotech Inc
Price (delayed)
$3.14
Market cap
$95.73M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.26
Enterprise value
-$66.7M
XBiotech is a fully integrated, global biopharmaceutical company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies. XBiotech currently is advancing a pipeline of therapies by harnessing naturally
Highlights
XBIT's quick ratio has dropped by 65% year-on-year
XBiotech's net income has plunged by 57% YoY and by 18% from the previous quarter
Key stats
What are the main financial stats of XBIT
Market
Valuations
Earnings
Shares outstanding
30.49M
Market cap
$95.73M
Enterprise value
-$66.7M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.53
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$42.47M
Net income
-$38.53M
EBIT
-$37.76M
EBITDA
-$36.01M
Free cash flow
-$32.27M
Per share
Balance sheet
Liquidity
EPS
-$1.26
EPS diluted
-$1.26
Free cash flow per share
-$1.06
Book value per share
$5.98
Revenue per share
$0
TBVPS
$6.54
Total assets
$199.09M
Total liabilities
$16.83M
Debt
$10.25M
Equity
$182.27M
Working capital
$159.46M
Debt to equity
0.06
Current ratio
11.56
Quick ratio
11.43
Net debt/EBITDA
4.51
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-18.1%
Return on equity
-19.8%
Return on invested capital
-183.9%
Return on capital employed
-20.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XBIT stock price
How has the XBiotech stock price performed over time
Intraday
3.97%
1 week
-1.57%
1 month
-10.8%
1 year
-62.93%
YTD
-20.51%
QTD
-3.09%
Financial performance
How have XBiotech's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$42.47M
Net income
-$38.53M
Gross margin
N/A
Net margin
N/A
XBiotech's net income has plunged by 57% YoY and by 18% from the previous quarter
The company's operating income fell by 13% YoY
Growth
What is XBiotech's growth rate over time
Valuation
What is XBiotech stock price valuation
P/E
N/A
P/B
0.53
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
XBiotech's EPS has shrunk by 56% YoY and by 17% QoQ
The P/B is 49% lower than the 5-year quarterly average of 1.0 and 49% lower than the last 4 quarters average of 1.0
The equity has declined by 17% year-on-year and by 5% since the previous quarter
Efficiency
How efficient is XBiotech business performance
The return on equity has dropped by 83% year-on-year and by 24% since the previous quarter
XBIT's ROA has shrunk by 72% YoY and by 22% QoQ
XBIT's ROIC is down by 15% QoQ
Dividends
What is XBIT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did XBiotech financials performed over time
XBIT's total liabilities has soared by 117% year-on-year but it is down by 5% since the previous quarter
XBIT's quick ratio has dropped by 65% year-on-year
The debt is 94% lower than the equity
The debt to equity has grown by 20% from the previous quarter
The equity has declined by 17% year-on-year and by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.